Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199

被引：1
|
作者：
Sparano, J. A.
Wang, M.
Martino, S.
Jones, V.
Perez, E.
Saphner, T.
Wolff, A. C.
Sledge, G. W., Jr.
Wood, W. C.
Davidson, N. E.
机构：
[1] Eastern Cooperat Oncol Grp, Brookline, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Southwest Oncol Grp, Ann Arbor, MI USA
[4] Canc & Acute Leukemia Grp B, Chicago, IL USA
[5] North Cent Canc Treatment Grp, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
516
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer
    Willemse, P. H.
    Munck, L.
    Creemers, G. J.
    Graaf, H.
    Smit, W.
    Erjavec, Z.
    Stouthard, J. M.
    Deijk, G.
    Bochove, A.
    Vader, W.
    Westermonn, A. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S70 - S70
  • [22] Doxorubicin and cyclophosphamide followed by weekly docetaxel (AC-T) as neoadjuvant chemotherapy in operable breast cancer patients:: GEICAM 2002-03 Study
    Estévez, LG
    Adrover, E
    Barnadas, A
    Cuevas, JM
    Seguí, MA
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S229 - S229
  • [23] Doxorubicin and cyclophosphamide followed by weekly docetaxel (AC-T) as neoadjuvant chemotherapy in operable breast cancer patients: Interim results from the 2002-03 GEICAM study
    Estevez, Laura G.
    Adrover, Encarna
    Barnandas, Agusti
    Cuevas, Jose M.
    Segui, Miguel A.
    ANNALS OF ONCOLOGY, 2004, 15 : 65 - 66
  • [24] Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American breast cancer intergroup trial E 2197
    Goldstein, Lori J.
    O'Neill, Anne
    Sparano, Joseph A.
    Perez, Edith A.
    Shulman, Lawrence N.
    Martino, Silvana
    Davidson, Nancy E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) : 4092 - 4099
  • [25] SWOG 0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer.
    Ellis, G. K.
    Green, S. J.
    Russell, C. A.
    Royce, M. E.
    Perez, E. A.
    Livingston, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 12S - 12S
  • [26] Results of clinical endpoints of a randomized phase It trial with doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer
    Schneeweiss, A.
    Ruiz, A.
    Rovira, P.
    Bottini, A.
    Manikhas, A.
    Wacker, J.
    Schumacher, T.
    Wolf, M.
    Segui, M.
    Sinn, P.
    Kennedy, L.
    Mansouri, K.
    Bauknecht, T.
    BREAST, 2009, 18 : S63 - S63
  • [27] Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer (vol 24, pg 5381, 2006)
    Jones
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1819 - 1819
  • [28] Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study
    Estevez, Laura G.
    Fortes, Jose Luis
    Adrover, Encarna
    Peiro, Gloria
    Margeli, Mireia
    Castella, Eva
    Cuevas, Jose Miguel
    Bernet, Laia
    Segui, Miguel Angel
    Andreu, Xavier
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (01): : 54 - 59
  • [29] Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study
    Laura G. Estevez
    José Luis Fortes
    Encarna Adrover
    Gloria Peiró
    Mireia Margelí
    Eva Castellá
    José Miguel Cuevas
    Laia Bernet
    Miguel Angel Segui
    Xavier Andreu
    Clinical and Translational Oncology, 2009, 11 : 54 - 59
  • [30] A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer
    Tu, Yifan
    Hershman, Dawn L.
    Bhalla, Kapil
    Fiskus, Warren
    Pellegrino, Christine M.
    Andreopoulou, Eleni
    Makower, Della
    Kalinsky, Kevin
    Fehn, Karen
    Fineberg, Susan
    Negassa, Abdissa
    Montgomery, Leslie L.
    Wiechmann, Lisa S.
    Alpaugh, R. Katherine
    Huang, Min
    Sparano, Joseph A.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (01) : 145 - 152
12345